Chemotherapy Monitoring With Breast Computed Tomography (CT)
The purpose of this study is to determine if dedicated breast computed tomography can be used successfully to monitor tumor response in breast cancer patients undergoing neoadjuvant chemotherapy.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Breast Cancer Chemotherapy Monitoring With Dedicated Breast Computed Tomography|
- Tumor response [ Time Frame: Mid-treatment and post-treatment completion ] [ Designated as safety issue: No ]
|Study Start Date:||June 2009|
|Estimated Study Completion Date:||September 2015|
|Estimated Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Breast cancer patients undergoing hormonal therapy before surgery.
Device: Dedicated breast computed tomography imaging
Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
Other Name: Koning CBCT,Cone Beam Breast CT
Before undergoing surgery to remove the tumor, it is common for breast cancer patients to first undergo chemotherapy or hormonal therapy. The main goal of the therapy is to reduce the size of the tumor before it is removed. Unfortunately, therapy response varies a lot between patients. The development of an effective therapy response monitoring method could reduce the time that a patient undergoes ineffectual therapy or unnecessary therapy after complete response.
Dedicated breast computed tomography (or breast CT), a new way of imaging the breast, has been introduced in the last few years. Breast CT is an x-ray exam that uses 3D imaging to show the breast in its real three dimensional shape. Combined with the use of special chemicals called iodine contrast enhancement, breast CT can provide images of both the anatomy and the blood flow in the breast. We propose to use breast CT to carefully monitor the response to therapy of breast cancer patients undergoing therapy before surgery.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00808041
|United States, Georgia|
|Emory University Winship Cancer Institute|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Ioannis Sechopoulos, PhD||Emory University|